C5a/C5ades-Arg-induced increase in blood pressure in the guinea pig: role of thromboxane.
Cleavage of the complement protein C5 by activation of the complement system yields a low molecular weight fragment C5a. Knowledge of the alterations in blood pressure induced by C5a as well as the mediators responsible for the blood pressure changes may provide information concerning the potential role of C5a in the adverse hemodynamic responses associated with complement activation. The purpose of this study was to characterize changes in mean arterial pressure in the guinea pig after intravenous challenge with a combination of guinea pig C5a plus C5a(des-Arg) (C5a/C5a(des-Arg)) and determine the mediators responsible for the transient increase in blood pressure which was observed. Mean arterial pressure was monitored in mechanically ventilated pentobarbital-anesthetized guinea pigs. Intravenous injection of C5a/C5a(des-Arg) consistently caused a marked but transient rise in blood pressure. A transient hypotensive response was also seen with injection of markedly higher doses of guinea pig C5a/C5a(des-Arg). Various pharmacological antagonists were used to determine the mediators responsible for the increase in blood pressure induced by guinea pig C5a/C5a(des-Arg). We found that the LTD4 antagonist L-649,923 did not inhibit the transient rise in blood pressure. However, the cyclooxygenase inhibitor indomethacin inhibited the C5a/C5a(des-Arg)-induced pressor response as did the thromboxane synthetase inhibitor U-63557A and the thromboxane receptor antagonist SQ 29,548. In addition, the C5a/C5a(des-Arg)-induced pressor response was not inhibited by the H1 antagonist pyrilamine, but was inhibited in part by the alpha-adrenergic antagonist phentolamine. Also, the response was reduced in animals depleted of circulating platelets or white blood cells. Thus, the results of our studies suggest that intravenously injected guinea pig C5a/C5a(des-Arg) causes release of the vasoconstrictor thromboxane, most likely from circulating white blood cells or platelets, resulting in a transient rise in blood pressure in the guinea pig. In addition, release of catecholamines may contribute to the pressor response observed.
Fraser
D G
DG
Department of Pharmacology, University of Minnesota, Duluth 55812.
Regal
J F
JF
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001095:Arachidonic Acids / Q000502:physiology; D001572:Benzofurans / Q000494:pharmacology; D001792:Blood Platelets / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects; D002395:Catecholamines / Q000502:physiology; D015936:Complement C5a / Q000502:physiology*; D015937:Complement C5a, des-Arginine / Q000502:physiology*; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007962:Leukocytes / Q000502:physiology; D008297:Male; D010654:Phenylbutyrates / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D013931:Thromboxanes / Q000502:physiology*
D000317:Adrenergic alpha-Antagonists; D001095:Arachidonic Acids; D001572:Benzofurans; D002395:Catecholamines; D015937:Complement C5a, des-Arginine; D006634:Histamine H1 Antagonists; D010654:Phenylbutyrates; D011994:Recombinant Proteins; D013931:Thromboxanes; D015936:Complement C5a; C050033:L 649923; D013930:Thromboxane-A Synthase; C039936:furegrelate; D007213:Indomethacin